Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

ClinicalTrials.gov ID: NCT05727176

Public ClinicalTrials.gov record NCT05727176. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.

Study identification

NCT ID: NCT05727176
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Taiho Oncology, Inc.; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

Interventions

TAS-120 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 4, 2023
Primary completion: Nov 30, 2026
Completion: Nov 30, 2026
Last update posted: Aug 31, 2026

2023 – 2026

United States locations

U.S. sites: 10
U.S. states: 5
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of California San Diego UCSD - Moores Cancer Center	La Jolla	California	92093	Completed
Tampa General Hospital Cancer Institute	Tampa	Florida	33606	Withdrawn
Henry Ford Health System	Detroit	Michigan	48202	Completed
Gabrail Cancer Center Research	Canton	Ohio	44718	Withdrawn
Texas Oncology	Abilene	Texas	79606-5208	Completed
The Liver Institute at Methodist Dallas Medical Center	Dallas	Texas	75203	Completed
Texas Oncology Methodist DFW	Dallas	Texas	75230	Completed
Texas Onc Methodist (Charlton)	Dallas	Texas	75237	Completed
Texas Oncology - Northeast	Denton	Texas	76201	Completed
Center for Oncology and Blood Disorders	Houston	Texas	77030	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05727176, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 31, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05727176 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →